Annovis Bio (NYSE: ANVS) has promoted Cheng Fang, Ph.D., to the role of chief scientific officer, effective immediately. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will now oversee scientific strategy and research operations across Annovis' Alzheimer's disease and Parkinson's disease programs. His responsibilities include translational science, clinical development, biomarker strategy and regulatory interactions, according to the company's announcement.
The promotion comes at a critical juncture for Annovis as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer's disease study and a subsequent New Drug Application submission. The company noted that Fang has played a key role in advancing its clinical development efforts and will lead scientific strategy through upcoming clinical and regulatory milestones.
Fang's appointment underscores Annovis' focus on neurodegenerative diseases. The company is a Phase 3 clinical-stage biotechnology firm headquartered in Malvern, Pennsylvania, developing treatments for Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The significance of this announcement lies in the timing of Fang's promotion as Annovis prepares for a pivotal data readout. The company's progress with buntanetap could impact the treatment landscape for Alzheimer's and Parkinson's diseases, which affect millions worldwide. Successful Phase 3 results and subsequent FDA approval would provide a new therapeutic option targeting multiple neurotoxic proteins simultaneously, potentially offering a disease-modifying approach rather than just symptomatic relief. For investors, the advancement toward a New Drug Application represents a key value inflection point, as regulatory milestones often drive stock performance and partnership opportunities.
More details on the announcement are available in the full press release at https://ibn.fm/c9jdt. For the latest news and updates relating to ANVS, visit the company's newsroom at https://ibn.fm/ANVS.
